Fig. 3

Kaplan–Meier analyses for recurrence-free interval in ER-positive, HER2-negative breast cancer patients according to tamoxifen treatment and (a) patients assigned to group FALSE (corresponding to the preferentially not activated heatmap group N) by use of our classification tool; and (b) patients assigned to group TRUE (corresponding to the preferentially activated heatmap group A) by use of our classification tool. The interrupted line specifies patients treated with tamoxifen. The continuous line shows patients randomised to the control arm